Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
19,218 Lung Cancer
clinical trials

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Clinical Trial
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: Enrolling, Phase I
Updated: 12/31/1969
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
Non Small Cell Lung Cancer Clinical Trial
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Status: Enrolling, Phase II
Updated: 12/31/1969
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Status: Enrolling, Phase II
Updated: 3/29/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Carcinoma, Non-Small-Cell Lung Clinical Trial
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Status: Enrolling, Phase III
Updated: 12/31/1969
Ophthalmic Consultants of Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Carcinoma, Non-Small-Cell Lung Clinical Trial
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Status: Enrolling, Phase III
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Franklin, TN
Click here to add this to my saved trials
Carcinoma, Non-Small-Cell Lung Clinical Trial
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Status: Enrolling, Phase III
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Hermitage, TN
Click here to add this to my saved trials
Carcinoma, Non-Small-Cell Lung Clinical Trial
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Status: Enrolling, Phase III
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Non-Small-Cell Lung Carcinoma Clinical Trial
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Los Angeles Hematology/Oncology Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lung Cancer Clinical Trial
Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Minneapolis Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology, Pulmonary / Respiratory Diseases Clinical Trial
The Lung Screening, Tobacco and Health Project
Status: Enrolling, Phase III
Updated: 12/31/1969
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Oncology, Pulmonary / Respiratory Diseases Clinical Trial
The Lung Screening, Tobacco and Health Project
Status: Enrolling, Phase III
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Oncology Clinical Trial
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Anchorage Radiation Therapy Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Parkland Health Center-Bonne Terre
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Hospital of Carbondale
mi
from
Carbondale, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Miami Valley Hospital South
mi
from
Centerville, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Centralia Oncology Clinic
mi
from
Centralia, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Bay Area Hospital
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle on Vermilion
mi
from
Danville, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Crossroads Cancer Center
mi
from
Effingham, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Dayton Physicians LLC-Atrium
mi
from
Franklin, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle Physician Group-Mattoon/Charleston
mi
from
Mattoon, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Community Medical Hospital
mi
from
Missoula, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Patrick Hospital - Community Hospital
mi
from
Missoula, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
New Ulm Medical Center
mi
from
New Ulm, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Valley Radiation Oncology
mi
from
Peru, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Swedish Medical Center-Ballard Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Swedish Medical Center - Cherry Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
North Shore Medical Center
mi
from
Skokie, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Lakeview Hospital
mi
from
Stillwater, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Methodist West Hospital
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Status: Enrolling, Phase II
Updated: 12/31/1969
Metro Health Hospital
mi
from
Wyoming, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Status: Enrolling, Phase I
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Providence Regional Cancer System-Aberdeen
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Lovelace Medical Center - Downtown
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Community Hospital of Anaconda
mi
from
Anaconda, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Cancer Care Center at Island Hospital
mi
from
Anacortes, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Alaska Regional Hospital
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Mount Sinai Comprehensive Cancer Center, Aventura
mi
from
Aventura, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Louis Cancer and Breast Institute-Ballwin
mi
from
Ballwin, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Baton Rouge General Medical Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Cleveland Clinic Cancer Center Beachwood
mi
from
Beachwood, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
UPMC-Heritage Valley Health System Beaver
mi
from
Beaver, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Upper Chesapeake Medical Center
mi
from
Bel Air, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Kaiser Permanente-Bellflower
mi
from
Bellflower, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Lafayette Family Cancer Center-EMMC
mi
from
Brewer, ME
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Ocean Medical Center
mi
from
Brick, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
United Hospital Center
mi
from
Bridgeport, WV
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Kaiser Permanente-Burke Medical Center
mi
from
Burke, VA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint James Community Hospital and Cancer Treatment Center
mi
from
Butte, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Aultman Health Foundation
mi
from
Canton, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Memorial Hospital of Carbondale
mi
from
Carbondale, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Enrolling, Phase III
Updated: 12/31/1969
Sandra L. Maxwell Cancer Center
mi
from
Cedar City, UT
Click here to add this to my saved trials
1 … 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 … 192